Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06566209 · ClinicalTrials.gov registry record
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
A clinical trial of Hematologic Malignancy and Myocarditis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06566209 is a study of Hematologic Malignancy and Myocarditis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06566209, a study of Hematologic Malignancy and Myocarditis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically relevant entity with a risk of progression to fulminant myocarditis.
Conditions Studied
Interventions
- DEVICE Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2027-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06566209
The ClinicalTrials.gov registry entry for NCT06566209 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) is the first listed.
NCT06566209 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06566209 about?
NCT06566209 is a clinical study titled "FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis". The purpose of this pilot study is to evaluate Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) as an imaging modality to diagnose and risk stratify subclinical, imaging negative ICI-myocarditis, and to determine whether subclinical ICI-induced myocarditis is a distinct and clinically rel...
What is the current status of trial NCT06566209?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-10-11. Estimated completion is 2027-04-30.
What conditions does trial NCT06566209 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Myocarditis, Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, ICI-Myocarditis, Solid Malignant Tumor.
What interventions are being tested in trial NCT06566209?
The interventions under investigation include: Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) (DEVICE).
Who is sponsoring clinical trial NCT06566209?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06566209 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.